Relationship of serum beta-synuclein with blood biomarkers and brain atrophy.
Alzheimers Dement
; 19(4): 1358-1371, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36129098
ABSTRACT
BACKGROUND:
Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).METHODS:
We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.RESULTS:
Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.DISCUSSION:
Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations. HIGHLIGHTS Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Degeneración Lobar Frontotemporal
/
Demencia Frontotemporal
/
Enfermedad de Alzheimer
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article